Gain access to Pharmaceuticals receives MuGard patent allowance Access Pharmaceuticals.

MuGard is Gain access to’ proprietary oral rinse product for the avoidance and treatment of oral mucositis, a debilitating side-effect which afflicts around 40 percent of cancer individuals undergoing radiation and chemotherapy. There is no well-accepted treatment for mucositis presently. Access is actively looking for marketing partners in European countries and the US.. Gain access to Pharmaceuticals receives MuGard patent allowance Access Pharmaceuticals, Inc offers announced that the Company has received a Notice of Allowance letter from the United States Patent and Trademark Office for its patent application entitled Liquid Formulations for the Avoidance and Treatment of Mucosal Illnesses and Disorders.Discussion In our study, patients with previously untreated metastatic melanoma with BRAF mutations who received combination therapy with trametinib and dabrafenib, as compared with vemurafenib monotherapy, had a member of family reduction of 31 percent in the chance of death. Together with the previously reported phase 2 and phase 3 trials of dabrafenib plus trametinib, in comparison with dabrafenib monotherapy,12,13 these data offer clear proof for the advantage of this mixture therapy over BRAF monotherapy in prolonging survival.